Z-2-(2,3-二氯苯基)亚甲基-3-氧代丁酸甲醚 | 68064-69-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: Z-2-(2,3-二氯苯基)亚甲基-3-氧代丁酸甲醚
• 中文别名: 非洛地平杂质1
• 英文名称: (Z)-methyl 2-(2,3-dichlorobenzylidene)-3-oxobutanoate
• 英文别名: methyl (Z)-2-(2,3-dichlorobenzylidene)-3-oxobutanoate；2-[(2,3-dichlorophenyl)methylene]-3-oxobutanoic acid,methyl ester；methyl 2-acetyl-3-(2,3-dichlorophenyl)-acrylate；2-acetyl-3(2,3-dichlorophenyl)acrylic acid methyl ester；methyl 2-(2,3-dichlorobenzylidene)acetoacetate；2-(2,3-dichlorobenzylidene)-acetoacetic acid methyl ester；Methyl 2-[(2,3-dichlorophenyl)methylidene]-3-oxobutanoate；methyl (2Z)-2-[(2,3-dichlorophenyl)methylidene]-3-oxobutanoate
• CAS: 68064-69-7
• 化学式: C₁₂H₁₀Cl₂O₃
• 分子量: 273.116
• InChiKey: QQXPSPWWWCQBFM-TWGQIWQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	(Z)-methyl 3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylate	1376615-40-5	C14H14Cl2O4	317.169
  ——	(E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylaldehyde	1376615-42-7	C13H12Cl2O3	287.142
  ——	(1E,2E)-2-(2,3-dichlorobenzylidene)-3-oxobutanal O-allyl oxime	1376615-45-0	C14H13Cl2NO2	298.169
  ——	(E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)prop-2-en-1-ol	1376615-41-6	C13H14Cl2O3	289.158
  ——	(1E,2E)-3-(2,3-dichlorophenyl)-2-(2-methyl-1,3-dioxolan-2-yl)acrylaldehyde oxime	1376615-43-8	C13H13Cl2NO3	302.157

反应信息

• 作为反应物：
  描述：

  Z-2-(2,3-二氯苯基)亚甲基-3-氧代丁酸甲醚 在 ammonium hydroxide 、 正丁基锂 、 silica gel 作用下， 反应 6.5h， 生成 2,6-dimethyl-4-(2,3-dichlorophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-methylester-5-isopropylester
  参考文献：
  名称：

  Synthesis of Optically Pure 1,4-Dihydropyridine Derivatives by Means of Diastereoisomeric Separation of the Hantzsch Intermediates Bearing (R)-1-Phenylethylamino Group

  摘要：

  Hantzsch intermediates, which were obtained by Michael addition reaction of benzylideneacetoacetates with the enamino esters bearing (R)-1-phenylethylamino group as a chiral auxiliary, were separated into two diastereoisomeric mixtures. Each of them underwent cyclization reaction to give optically pure 1,4-dihydropyridine derivatives.

  DOI：

  10.3987/com-94-s(b)51
• 作为产物：
  描述：

  乙酰乙酸甲酯 、 2,3-二氯苯甲醛 在 哌啶 、 溶剂黄146 作用下， 以80%的产率得到Z-2-(2,3-二氯苯基)亚甲基-3-氧代丁酸甲醚
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF 4 -SUBSTITUTED -1, 4-DIHYDROPYRIDINES
  [FR] PROCÉDÉ POUR LA PRÉPARATION DE 1,4-DIHYDROPYRIDINES SUBSTITUÉES EN POSITION 4

  摘要：

  通过环加成反应制备公式I的4-取代-1,4-二氢吡啶，该环化反应在室温下可在水中无需任何催化剂的情况下完全进行。为了举例说明，本发明特别详细地描述了制备公式II的非洛地平的方法。非洛地平是一种血管扩张剂，通过烷基3-氨基丙烯酸酯与二氯苯甲醛进行环加成反应制备，反应条件下产物结晶出来并可通过过滤直接分离。

  公开号：

  WO2012123966A1

文献信息

• DRUG DERIVATIVES
  申请人：Craighead Mark

  公开号：US20130225594A1

  公开（公告）日：2013-08-29

  The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.

  本发明涉及已知活性药物化合物的衍生物。这些衍生物通过是活性化合物的氧化还原衍生物与母体活性化合物相区别。这意味着活性化合物中的一个或多个官能团已转化为另一组，在一项或多项反应中，这可以被认为代表氧化态的变化。我们通常将这些化合物称为氧化还原衍生物。发明中的衍生物可能与原始母体活性药物化合物仅通过单一步骤转换有关，或者可能通过包括一个或多个氧化态变化的几个合成步骤与之相关。在某些情况下，经过两个或更多转换后获得的官能团可能与母体活性化合物处于相同的氧化态（我们将这些化合物包括在我们的氧化还原衍生物定义中）。在其他情况下，发明的衍生物的氧化态可以被认为是与母体化合物不同的。在许多情况下，发明中的化合物本身就具有固有的治疗活性。在某些情况下，相对于母体化合物的相同靶点或靶点，这种活性与母体化合物针对该靶点或靶点的活性一样好或更好。
• 2-thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05202330A1

  公开（公告）日：1993-04-13

  Pyrimidine compounds of the formula ##STR1## wherein X is sulfur or oxygen, Y is R.sub.11 or --O--R.sub.1, and R.sub.4 is aryl or heterocyclo are disclosed. These compounds are useful as cardiovascular agents, particularly anti-hypertensive agents, due to their calcium entry blocking vasodilator activity.

  公开了符合以下公式的嘧啶化合物##STR1##其中X是硫或氧，Y是R.sub.11或--O--R.sub.1，R.sub.4是芳香族或杂环。这些化合物由于其钙通道阻滞血管扩张剂活性而被用作心血管药物，特别是抗高血压药物。
• Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents
  作者：John E. Arrowsmith、Simon F. Campbell、Peter E. Cross、John K. Stubbs、Roger A. Burges、Donald G. Gardiner、Kenneth J. Blackburn

  DOI：10.1021/jm00159a022

  日期：1986.9

  A series of dihydropyridines substituted at the 2-position by basic side chains are described and their potencies as calcium antagonists listed. One compound, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5- methoxycarbonyl-6-methyl-1,4-dihydropyridine (17, amlodipine) was found to be comparable in potency to nifedipine and to have an elimination half-life of 30 h in dogs. Oral bioavailability

  描述了一系列在2-位被碱性侧链取代的二氢吡啶，并列出了其作为钙拮抗剂的效力。发现一种化合物2-[（（2-氨基乙氧基）甲基] -4-（2-氯苯基）-3-乙氧基羰基-5-甲氧基羰基-6-甲基-1,4-二氢吡啶（17，氨氯地平）具有可比性。对硝苯地平有效，并具有30 h的消除半衰期。口服生物利用度接近100％，血液动力学反应起效缓慢，效果持久。已经制备了两种对映异构体，并且发现大部分活性与（-）异构体18有关。对17的相似类似物进行的X射线晶体学研究表明，两者之间存在弱氢键侧链氧和质子在环氮上。
• Dihydropyridine anti-ischaemic and antihypertensive agents
  申请人：Pfizer Inc.

  公开号：US04616024A1

  公开（公告）日：1986-10-07

  1,4-Dihydropyridine derivatives of the formula: ##STR1## wherein R is aryl or heteroaryl: R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl; Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --; n is 1 to 3; and X is a 5 or 6 membered nitrogen containing aromatic heterocyclic ring which may optionally be substituted by one or more C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, CN, --N(R.sup.3).sub.2, (CH.sub.2).sub.m CO.sub.2 H, (CH.sub.2).sub.m CO.sub.2 (C.sub.1 -C.sub.4 alkyl) or (CH.sub.2).sub.m CON(R.sup.3).sub.2 group wherein each R.sup.3 is independently H or C.sub.1 -C.sub.4 alkyl and m is 0 or 1; and their pharmaceutically acceptable acid addition salts, and pharmaceutical preparation containing such compounds, have utility as anti-ischaemic and antihypertensive agents.

  1,4-二氢吡啶衍生物的化学式：其中R为芳基或杂环芳基；R.sup.1和R.sup.2分别独立为C.sub.1-C.sub.4烷基或2-甲氧乙基；Y为--(CH.sub.2).sub.n --，--CH.sub.2 CH(CH.sub.3)--或--CH.sub.2 C(CH.sub.3).sub.2 --；n为1至3；X为含有5或6个成员的含氮芳香杂环环，可以选择性地被一个或多个C.sub.1-C.sub.4烷基，苯基，苄基，CN，--N(R.sup.3).sub.2，(CH.sub.2).sub.m CO.sub.2 H，(CH.sub.2).sub.m CO.sub.2 (C.sub.1-C.sub.4烷基)或(CH.sub.2).sub.m CON(R.sup.3).sub.2基取代；其中每个R.sup.3独立地为H或C.sub.1-C.sub.4烷基，m为0或1；它们的药学上可接受的酸盐和含有这种化合物的药物制剂在抗缺血和降压剂方面具有用途。
• Synthese von substituierten 2-Aminonicotinonitrilen
  作者：Reinhard Troschütz、Thomas Dennstedt

  DOI：10.1002/ardp.19943270107

  日期：——

  Mono‐, di‐ und trisubstituierte 2‐Aminonicotinonitrile vom Typ 8, 13, 14 und 19 lassen sich aus Keton‐Mannich‐Basen Hydrochloriden 4 · HCl, Enonen 12, β‐Aminovinylketonen 17, 3‐Aminoacrolein‐Derivaten 18 sowie Vinamidinium Perchloraten 21 und in situ erzeugtem 3,3‐Diamino‐acrylnitril (3) herstellen.

  可以从酮曼尼希碱、盐酸盐 4 HCl、烯酮 12、β-氨基乙烯基酮 17、3-氨基丙烯醛衍生物 18 和 vinamidinium 和高氯酸盐中获得 8、13、14 和 19 型的单、二和三取代的 2-氨基烟腈3,3-二氨基-丙烯腈 (3) 原位生成。